{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:54:09Z","timestamp":1792108449865,"version":"4.4.0"},"reference-count":162,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T00:00:00Z","timestamp":1687564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"MD Anderson Cancer Center","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Myelofibrosis (MF) presents an array of clinical manifestations and molecular profiles. The two distinct phenotypes\u2212 myeloproliferative and myelodepletive or cytopenic\u2212 are situated at the two poles of the disease spectrum and are largely defined by different degrees of cytopenias, splenomegaly, and distinct molecular profiles. The myeloproliferative phenotype is characterized by normal\/higher peripheral blood counts or mildly decreased hemoglobin, progressive splenomegaly, and constitutional symptoms. The myeloproliferative phenotype is typically associated with secondary MF, higher JAK2 V617F burden, fewer mutations, and superior overall survival (OS). The myelodepletive phenotype is usually associated with primary MF, \u22652 cytopenias, modest splenomegaly, lower JAK2 V617F burden, higher fibrosis, greater genomic complexity, and inferior OS. Cytopenias are associated with mutations in epigenetic regulators\/splicing factors, clonal evolution, disease progression, and shorter OS. Clinical variables, in conjunction with the molecular profiles, inform integrated prognostication and disease management. Ruxolitinib\/fedratinib and pacritinib\/momelotinib may be more suitable to treat patients with the myeloproliferative and myelodepletive phenotypes, respectively. Appreciation of MF heterogeneity and two distinct phenotypes, the different clinical manifestations and molecular profiles associated with each phenotype alongside the growing treatment expertise, the development of non-myelosuppressive JAK inhibitors, and integrated prognostication are leading to a new era in patient management. Physicians can increasingly tailor personalized treatments that will address the unique unmet needs of MF patients, including those presenting with the myelodepletive phenotype, to elicit optimal outcomes and extended OS across the disease spectrum.<\/jats:p>","DOI":"10.3390\/cancers15133331","type":"journal-article","created":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T03:14:56Z","timestamp":1687749296000},"page":"3331","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Association of Myelofibrosis Phenotypes with Clinical Manifestations, Molecular Profiles, and Treatments"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8044-4960","authenticated-orcid":false,"given":"Helen T.","family":"Chifotides","sequence":"first","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6912-8569","authenticated-orcid":false,"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4343-5712","authenticated-orcid":false,"given":"Prithviraj","family":"Bose","sequence":"additional","affiliation":[{"name":"Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,24]]},"reference":[{"key":"ref_1","unstructured":"Kantarjian, H.M., Wolff, R.A., and Rieber, A.G. (2022). The MD Anderson Manual of Medical Oncology, McGraw-Hill, LLC. [4th ed.]."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.clml.2020.01.008","article-title":"The myelodepletive phenotype in myelofibrosis: Clinical relevance and therapeutic implication","volume":"20","author":"Marcellino","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41375-022-01767-y","article-title":"Biological drivers of clinical phenotype in myelofibrosis","volume":"37","author":"Mascarenhas","year":"2023","journal-title":"Leukemia"},{"key":"ref_4","first-page":"5929","article-title":"Pacritinib demonstrates spleen volume reduction in patients with myelofibrosis independent of JAK2 V617F allele burden","volume":"4","author":"Tremblay","year":"2020","journal-title":"Blood Adv."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.leukres.2017.10.002","article-title":"Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs","volume":"63","author":"Scotch","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.leukres.2017.06.001","article-title":"Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis","volume":"59","author":"Masarova","year":"2017","journal-title":"Leuk. Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1182\/blood-2014-02-554634","article-title":"Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis","volume":"123","author":"Rampal","year":"2014","journal-title":"Blood"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s12185-019-02758-z","article-title":"Mutational profiling in myelofibrosis: Implications for management","volume":"111","author":"Bose","year":"2020","journal-title":"Inter. J. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ajh.24377","article-title":"Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thromobocythemia myelofibrosis: A study on 359 patients of the AGIMM group","volume":"91","author":"Rotunno","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3324\/haematol.13721","article-title":"JAK2V617F mutational status and allele burden have little influence on clinical phenotype and prognosis in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis","volume":"94","author":"Guglielmelli","year":"2009","journal-title":"Haematologica"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood-2021-146600","article-title":"A myelodepletive phenotype is associated with distinctive molecular features and outcomes in patients with myelofibrosis","volume":"138","author":"Coltro","year":"2021","journal-title":"Blood"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41408-019-0236-2","article-title":"Myelofibrosis in 2019: Moving beyond JAK2 inhibition","volume":"9","author":"Schieber","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1186\/s12967-018-1729-7","article-title":"The ruxolitinib effect: Understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms","volume":"16","author":"Greenfield","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/bs.ircmb.2021.02.008","article-title":"Mutational landscape of blast phase myeloproliferative neoplasms (BP-MPN) and antecedent MPN","volume":"366","author":"Pasca","year":"2022","journal-title":"Inter. Rev. Cell Mol. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1182\/blood.2019000943","article-title":"Leukemia secondary to myeloproliferative neoplasms","volume":"136","author":"Dunbar","year":"2020","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1056\/NEJMoa1716614","article-title":"Classification and personalized prognosis in myeloproliferative neoplasms","volume":"379","author":"Grinfeld","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood.2022017578","article-title":"Genetic basis and molecular profiling in myeloproliferative neoplasms","volume":"141","author":"Paz","year":"2023","journal-title":"Blood"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/s41586-020-2864-x","article-title":"Single-cell mutation analysis of clonal evolution in myeloid malignancies","volume":"587","author":"Miles","year":"2020","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41467-019-13892-x","article-title":"Single-cell analysis based dissection of clonality in myelofibrosis","volume":"11","author":"Mylonas","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/s41586-021-04312-6","article-title":"Life histories of myeloproliferative neoplasms inferred from phylogenies","volume":"602","author":"Williams","year":"2022","journal-title":"Nature"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.hoc.2021.01.001","article-title":"Epigenetic dysregulation of myeloproliferative neoplasms","volume":"35","author":"Dunbar","year":"2021","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-021-01116-z","article-title":"Molecular pathogenesis of myeloproliferative neoplasms","volume":"14","author":"Greenfield","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Loscocco, G., Coltro, G., Guglielmelli, P., and Vannucchi, A.M. (2021). Integration of molecular information in risk assessment of patients with myeloproliferative neoplasms. Cells, 10.","DOI":"10.3390\/cells10081962"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1182\/bloodadvances.2016000208","article-title":"Targeted deep sequencing in primary myelofibrosis","volume":"1","author":"Tefferi","year":"2016","journal-title":"Blood Adv."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","article-title":"Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias","volume":"70","author":"Manshouri","year":"2010","journal-title":"Cancer Res."},{"key":"ref_28","first-page":"1443","article-title":"Genomic analysis of primary and secondary myelofibrosis redefines the prognostic impact of ASXL1 mutations: A FIM study","volume":"5","author":"Paz","year":"2021","journal-title":"Blood Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1182\/bloodadvances.2021006350","article-title":"ASXL1 mutations are prognostically significant in PMF but not MF following essential thrombocythemia or polycythemia vera","volume":"6","author":"Guglielmelli","year":"2022","journal-title":"Blood Adv."},{"key":"ref_30","first-page":"2454","article-title":"ASXL1 mutation confers poor prognosis in primary myelofibrosis patients with low JAK2V617F allele burden but not in those with high allele burden","volume":"99","author":"Wang","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41408-019-0175-y","article-title":"Leukemic transformation among 1306 patients with primary myelofibrosis: Risk factors and development of a predictive model","volume":"9","author":"Vallapureddy","year":"2019","journal-title":"Blood Cancer J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1182\/blood-2012-05-429696","article-title":"SRSF2 mutations in primary myelofibrosis: Significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival","volume":"120","author":"Lasho","year":"2012","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"E347","DOI":"10.1002\/ajh.26648","article-title":"SF3B1 mutations in primary and secondary myelofibrosis: Clinical, molecular and prognostic correlates","volume":"97","author":"Loscocco","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1159\/000512929","article-title":"Accelerated phase of myeloproliferative neoplasms","volume":"144","author":"Shahin","year":"2021","journal-title":"Acta Haematologica"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/leu.2011.253","article-title":"IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: Clinical evidence for leukemogenic collaboration with JAK2 V617F","volume":"26","author":"Tefferi","year":"2012","journal-title":"Leukemia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1172\/JCI94516","article-title":"JAK2\/IDH-mutant\u2013driven myeloproliferative neoplasm is sensitive to combined targeted inhibition","volume":"128","author":"McKenney","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20151136","article-title":"Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis","volume":"213","author":"Shimizu","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/ejh.13579","article-title":"Combination of myeloproliferative neoplasm driver gene activation with mutations of splice factor or epigenetic modifier genes increases risk of rapid blastic progression","volume":"106","author":"Bartels","year":"2021","journal-title":"Eur. J. Haematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1182\/bloodadvances.2018024018","article-title":"Advanced forms of MPNs are accompanied by chromosomal abnormalities that lead to dysregulation of TP53","volume":"2","author":"Marcellino","year":"2018","journal-title":"Blood Adv."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1002\/cncr.31986","article-title":"Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia","volume":"125","author":"Benton","year":"2019","journal-title":"Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.ccell.2018.10.008","article-title":"JARID2 functions as a tumor suppressor in myeloid neoplasms by repressing self-renewal in hematopoietic progenitor cells","volume":"34","author":"Celik","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1158\/2159-8290.CD-20-1353","article-title":"LKB1\/STK11 is a tumor suppressor in the progression of myeloproliferative neoplasms","volume":"11","author":"Marinaccio","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: An international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2018","journal-title":"Leukemia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1182\/bloodadvances.2018021469","article-title":"The mutational landscape of accelerated and blast-phase myeloproliferative neoplasms impacts patient outcomes","volume":"2","author":"McNamara","year":"2018","journal-title":"Blood Adv."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/s41375-019-0603-9","article-title":"Prognostic impact of RAS-pathway mutations in patients with myelofibrosis","volume":"34","author":"Santos","year":"2020","journal-title":"Leukemia"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1182\/bloodadvances.2020002175","article-title":"RAS\/CBL mutations predict resistance to JAK inhibitors in myelofibrosis and are associated with poor prognostic features","volume":"4","author":"Coltro","year":"2020","journal-title":"Blood Adv."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/leu.2014.3","article-title":"CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: Clinical, cytogenetic and molecular comparisons","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"E314","DOI":"10.1002\/ajh.25625","article-title":"Driver mutation-specific clinical and genomic correlates differ between primary and secondary myelofibrosis","volume":"94","author":"Kuykendall","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1182\/blood-2009-04-216044","article-title":"Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele","volume":"114","author":"Guglielmelli","year":"2009","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1182\/blood-2014-05-578435","article-title":"Clinical effect of driver mutations of JAK2, CALR or MPL in primary myelofibrosis","volume":"124","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"28789","DOI":"10.1038\/srep28789","article-title":"ASXL1 plays an important role in erythropoiesis","volume":"6","author":"Shi","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1084\/jem.20131141","article-title":"Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo","volume":"210","author":"Gao","year":"2013","journal-title":"J. Exp. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3071","DOI":"10.1128\/MCB.00202-15","article-title":"SRSF2 is essential for hematopoiesis, and its myelodysplastic syndrome-related mutations dysregulate alternative pre-mRNA splicing","volume":"35","author":"Komeno","year":"2015","journal-title":"Mol. Cell Biol."},{"key":"ref_56","first-page":"E10437","article-title":"Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene U2af1","volume":"115","author":"Zhen","year":"2018","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1182\/blood-2011-12-400994","article-title":"Mutations affecting mRNA spicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes","volume":"119","author":"Damm","year":"2012","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40364-018-0142-y","article-title":"SRSF2 mutations in myelodysplasia\/myeloproliferative neoplasms","volume":"6","author":"Aujla","year":"2018","journal-title":"Biomark. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.1080\/10428194.2022.2095629","article-title":"Impact of SF3B1 mutation in myelofibrosis","volume":"63","author":"Senapati","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2013.286","article-title":"U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1038\/s41375-018-0078-0","article-title":"U2AF1 mutation types in primary myelofibrosis: Phenotypic and prognostic distinctions","volume":"32","author":"Tefferi","year":"2018","journal-title":"Leukemia"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1002\/cncr.34414","article-title":"Disease-related thrombocytopenia in myelofibrosis is defined by distinct genetic etiologies and is associated with unique prognostic correlates","volume":"128","author":"Kuykendall","year":"2022","journal-title":"Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.1002\/cncr.33094","article-title":"Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era","volume":"126","author":"Masarova","year":"2020","journal-title":"Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/gcc.22789","article-title":"Targeted molecular characterization shows differences between primary and secondary myelofibrosis","volume":"59","author":"Courtier","year":"2019","journal-title":"Genes Chromosomes Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"5227","DOI":"10.1182\/blood-2011-06-363424","article-title":"EZH2 mutational status predicts poor survival in myelofibrosis","volume":"118","author":"Guglielmelli","year":"2011","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.3324\/haematol.2021.280320","article-title":"ASXL1 mutations accelerate bone marrow fibrosis vis EGR1-TNFA axis mediated neoplastic fibrocyte generation in myeloproliferative neoplasms","volume":"108","author":"Shi","year":"2023","journal-title":"Haematologica"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41408-023-00829-3","article-title":"Non-driver mutations landscape in different stages of primary myelofibrosis determined ASXL1 mutations play a critical role in disease progression","volume":"13","author":"Yan","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1182\/blood.2020010402","article-title":"Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms","volume":"138","author":"Marcault","year":"2021","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1182\/blood-2013-07-515676","article-title":"JAK2 p.617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms","volume":"122","author":"Takahashi","year":"2013","journal-title":"Blood"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3324\/haematol.2014.113845","article-title":"Molecular determinants of pathogenesis and clinical phenotype in myeloproliferative neoplasms","volume":"102","author":"Grinfeld","year":"2017","journal-title":"Haematologica"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s00277-017-3193-5","article-title":"Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up","volume":"97","author":"Bellosillo","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","article-title":"JAK2V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis","volume":"110","author":"Barosi","year":"2007","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2016.149765","article-title":"An accurate simple prognostic model consisting of age, JAK2, CALR and MPL mutation status for patients with primary myelofibrosis","volume":"102","author":"Rozovski","year":"2017","journal-title":"Haematologica"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/sj.leu.2405097","article-title":"Low JAK2V617F allele burden in primary myelofibrosis, compared to either a higher allele burden or unmutated status, is associated with inferior overall and leukemia-free survival","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41408-023-00786-x","article-title":"Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis","volume":"13","author":"Guglielmelli","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Kim, H.-Y., Han, Y., Jang, J.H., Jung, C.W., Kim, S.-H., and Kim, H.-J. (2022). Effects of CALR-mutant type and burden on the phenotype of myeloproliferative neoplasms. Diagnostics, 12.","DOI":"10.3390\/diagnostics12112570"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"12367","DOI":"10.2147\/OTT.S287944","article-title":"Impact of mutational profile on the management of myeloproliferative neoplasms: A short review of the emerging data","volume":"13","author":"Loscocco","year":"2020","journal-title":"OncoTargets Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1182\/hematology.2022000339","article-title":"Molecular prognostication in Ph-negative MPNs in 2022","volume":"2022","author":"Vannucchi","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1182\/blood.2022017423","article-title":"Myelofibrosis","volume":"141","author":"Passamonti","year":"2023","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.6004\/jnccn.2020.7557","article-title":"A practical guide for using myelofibrosis prognostic models in the clinic","volume":"18","author":"How","year":"2020","journal-title":"J. Natl. Camp. Netw."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e818","DOI":"10.1097\/HS9.0000000000000818","article-title":"Machine learning improves risk stratification in myelofibrosis: An analysis of the Spanish, Registry of Myelofibrosis","volume":"7","author":"Raya","year":"2023","journal-title":"HemaSphere"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41408-022-00743-0","article-title":"Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score","volume":"12","author":"Barbui","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5336","DOI":"10.1182\/bloodadvances.2020001528","article-title":"Outcome of patients with IDH1\/2-mutated post-myeloproliferative neoplasm AML in the era of IDH inhibitors","volume":"4","author":"Chifotides","year":"2020","journal-title":"Blood Adv."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/hematology.2022000341","article-title":"Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: Current and emerging concepts","volume":"2022","author":"Bewersdorf","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1111\/bjh.16709","article-title":"Clinical outcomes of IDH2-mutated advanced phase Ph-negative myeloproliferative neoplasm treated with enasidenib","volume":"190","author":"Patel","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1182\/blood-2022-164678","article-title":"Molecularly targeted combination therapy for advanced phase myeloproliferative neoplasm: MPN-RC 119","volume":"140","author":"Mascarenhas","year":"2022","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11899-022-00685-1","article-title":"Molecular pathogenesis of myeloproliferative neoplasms","volume":"17","author":"Rolles","year":"2022","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1200\/JCO.21.02246","article-title":"\u201cDisease modification\u201d in myelofibrosis: An elusive goal?","volume":"40","author":"Vachhani","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Rumi, E., Trotti, C., Vanni, D., Casetti, I.C., Pietra, D., and Sant\u2019Antonio, E. (2020). The genetic basis of primary myelofibrosis and its clinical relevance. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21238885"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.clml.2021.06.008","article-title":"SOHO State of the Art, Updates and Next, Questions: Identifying and treating \u201cprogression\u201d in myelofibrosis","volume":"21","author":"Bose","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1097\/HS9.0000000000000424","article-title":"JAK inhibition for the treatment of myelofibrosis: Limitations and future perspectives","volume":"4","author":"Bose","year":"2020","journal-title":"HemaSphere"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e778","DOI":"10.1097\/HS9.0000000000000778","article-title":"Treating anemic patients with myelofibrosis in the new Janus kinase inhibitor era: Current evidence and real-world implications","volume":"6","author":"Gerds","year":"2022","journal-title":"HemaSphere"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s11899-018-0447-9","article-title":"Management of myelofibrosis-related cytopenias","volume":"13","author":"Bose","year":"2018","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1007\/s00277-023-05126-4","article-title":"How I manage anemia related to myelofibrosis and its treatment regimens","volume":"102","author":"Verstovsek","year":"2023","journal-title":"Ann. Hematol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"103862","DOI":"10.1016\/j.critrevonc.2022.103862","article-title":"Anemia in myelofibrosis: Current and emerging treatment options","volume":"180","author":"Passamonti","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/bjh.14601","article-title":"Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia","volume":"181","author":"Correa","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41408-022-00713-6","article-title":"Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis","volume":"12","author":"Coltro","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/HS9.0000000000000001","article-title":"Myelofibrosis-related anemia: Current and emerging therapeutic strategies","volume":"1","author":"Naymagon","year":"2017","journal-title":"HemaSphere"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/s41375-018-0028-x","article-title":"Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: Analysis based on 1109 consecutive patients","volume":"32","author":"Nicolosi","year":"2018","journal-title":"Leukemia"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3324\/haematol.2010.031831","article-title":"Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS","volume":"96","author":"Elena","year":"2011","journal-title":"Haematologica"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: The Mayo clinic experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin. Proc."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/ejh.13005","article-title":"Significance of thrombocytopenia in patients with primary and post-essential thrombocythemia\/polycythemia vera myelofibrosis","volume":"100","author":"Masarova","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e507","DOI":"10.1016\/j.clml.2022.01.016","article-title":"Thrombocytopenia in patients with myelofibrosis: Pathogenesis, prevalence, prognostic impact, and treatment","volume":"22","author":"Sastow","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"5587","DOI":"10.1200\/JCO.2009.22.8833","article-title":"Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"27","author":"Tam","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2015-03-633404","article-title":"Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib","volume":"126","author":"Patel","year":"2015","journal-title":"Blood"},{"key":"ref_106","first-page":"1729","article-title":"Impact of genomic alterations on outcomes in myelofibrosis patients receiving JAK1\/2 inhibitor therapy","volume":"1","author":"Spiegel","year":"2017","journal-title":"Blood"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/s41408-018-0152-x","article-title":"Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea","volume":"8","author":"Pacilli","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1182\/blood-2017-05-783225","article-title":"Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation","volume":"130","author":"Patel","year":"2017","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1038\/leu.2016.45","article-title":"JAK2(V617F) allele burden \u2265 50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy","volume":"30","author":"Barosi","year":"2016","journal-title":"Leukemia"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/01.HS9.0000846908.10695.dd","article-title":"P1010: Ruxolitinib in myelodepletive myelofibrosis: Response, toxicity and outcome","volume":"6","author":"Palandri","year":"2022","journal-title":"HemaSphere"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1002\/cncr.34722","article-title":"Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome","volume":"129","author":"Palandri","year":"2023","journal-title":"Cancer"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"20406207221118429","DOI":"10.1177\/20406207221118429","article-title":"Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 \u00d7 109\/L to < 100 \u00d7 109\/L) at baseline: The final analysis of EXPAND","volume":"13","author":"Guglielmelli","year":"2022","journal-title":"Ther. Adv. Hematol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.16462","article-title":"Primary analysis of JUMP a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts","volume":"189","author":"Griesshammer","year":"2020","journal-title":"Br. J. Haematol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/bjh.18207","article-title":"Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts","volume":"198","author":"Harrison","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1002\/cncr.32664","article-title":"Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis","volume":"126","author":"Palandri","year":"2020","journal-title":"Cancer"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1182\/bloodadvances.2021006889","article-title":"A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis","volume":"6","author":"Maffioli","year":"2022","journal-title":"Blood Adv."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.clml.2021.10.002","article-title":"SOHO State of the Art, Updates and Next, Questions: Novel therapies in development for myelofibrosis","volume":"22","author":"Chifotides","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.clml.2022.12.014","article-title":"SOHO State of the Art, Updates and Next, Questions: Novel, therapeutic strategies in development for myelofibrosis","volume":"23","author":"Chifotides","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1182\/blood.2022017416","article-title":"Biology and therapeutic targeting of molecular mechanisms in MPNs","volume":"141","author":"How","year":"2023","journal-title":"Blood"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11899-022-00671-7","article-title":"Novel therapies in myelofibrosis: Beyond, JAK myelofibrosis","volume":"17","author":"Waksal","year":"2022","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1080\/14656566.2023.2213435","article-title":"Moving beyond ruxolitinib failure in myelofibrosis: Evolving strategies for second line therapy","volume":"24","author":"Bose","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1182\/bloodadvances.2020002662","article-title":"ACVR1\/JAK1\/JAK2 inhibitor momelotinib reverses transfusion dependency and suppresses hepcidin in myelofibrosis phase 2 trial","volume":"4","author":"Oh","year":"2020","journal-title":"Blood Adv."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-021-01157-4","article-title":"Momelotinib: An emerging treatment for myelofibrosis patients with anemia","volume":"15","author":"Chifotides","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1182\/blood-2022-156936","article-title":"Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis","volume":"140","author":"Oh","year":"2022","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/17474086.2022.2112565","article-title":"Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia","volume":"15","author":"Mascarenhas","year":"2022","journal-title":"Exp. Rev. Hematol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"4905","DOI":"10.1182\/bloodadvances.2022007524","article-title":"The, Odyssey of pacritinib in myelofibrosis","volume":"6","author":"Venugopal","year":"2022","journal-title":"Blood Adv."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaoncol.2017.5818","article-title":"Pacritinib vs. best available therapy, including ruxolitinib, in patients with myelofibrosis: A randomized clinical trial","volume":"4","author":"Mascarenhas","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"5825","DOI":"10.1182\/bloodadvances.2020003314","article-title":"Determining the recommended dose of pacritinib: Results from the PAC203 dose-finding trial in advanced myelofibrosis","volume":"4","author":"Gerds","year":"2020","journal-title":"Blood Adv."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1016\/S2352-3026(17)30027-3","article-title":"Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): An international, randomised, phase 3 trial","volume":"4","author":"Mesa","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1182\/blood.V128.22.3131.3131","article-title":"Relationship of JAK2V617F allelic burden (AB) to demographics, disease characteristics, and response to therapy in PERSIST-1, a randomized phase III study of pacritinib (PAC) versus best available therapy (BAT) in patients (pts) with primary and secondary myelofibrosis (MF)","volume":"128","author":"Vannucchi","year":"2016","journal-title":"Blood"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1182\/blood-2019-127609","article-title":"The oral JAK2\/IRAK1 inhibitor pacritinib demonstrates spleen volume reduction in myelofibrosis patients independent of JAK2V617F allele burden","volume":"134","author":"Verstovsek","year":"2019","journal-title":"Blood"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.3324\/haematol.2021.279415","article-title":"Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia","volume":"107","author":"Verstovsek","year":"2022","journal-title":"Haematologica"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"S352","DOI":"10.1016\/S2152-2650(21)01815-2","article-title":"MPN-038, PACIFICA: A randomized, controlled phase 3 study of pacritinib versus physician\u2019s choice in patients with primary or secondary myelofibrosis with severe thrombocytopenia","volume":"21","author":"Mascarenhas","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"10612","DOI":"10.1002\/cam4.5799","article-title":"Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies","volume":"12","author":"Mesa","year":"2023","journal-title":"Cancer Med."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2217\/fon-2020-1048","article-title":"MOMENTUM: Momelotinib vs. danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic","volume":"17","author":"Verstovsek","year":"2021","journal-title":"Future Oncol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): Results from an international, double-blind, randomised, controlled phase 3 study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"Lancet"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2017.73.4418","article-title":"SIMPLIFY-1, A phase III randomized trial of momelotinib versus ruxolitinib in Janus kinase inhibitor-na\u00efve patients with myelofibrosis","volume":"35","author":"Mesa","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(17)30237-5","article-title":"Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): A randomized, open-label, phase 3 trial","volume":"5","author":"Harrison","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Verstovsek, S., Mesa, R.A., Gupta, V., Lavie, D., Dubruille, V., Cambier, N., Platzbecker, U., Hus, M., Xicoy, B., and Oh, S.T. (2023). Momelotinib long-term safety and survival in myelofibrosis: Integrated analysis of phase 3 randomized-controlled trials. Blood Adv., in press.","DOI":"10.1182\/bloodadvances.2022009311"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-135880","article-title":"Momelotinib\u2019s spleen, symptom and anemia efficacy is maintained in intermediate\/high-risk myelofibrosis patients with thrombocytopenia","volume":"136","author":"Kiladjian","year":"2020","journal-title":"Blood"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"S340","DOI":"10.1016\/S2152-2650(22)01464-1","article-title":"MPN-483 Thrombocytopenic myelofibrosis (MF) patients previously treated with a JAK inhibitor in a phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) [MOMENTUM]","volume":"22","author":"Gerds","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Hatzimichael, E., Timotheatou, D., Koumpis, E., Benetatos, L., and Makris, A. (2022). Luspatercept: A new tool for the treatment of anemia related to b-thalassemia, myelodysplastic syndromes and primary myelofibrosis. Diseases, 10.","DOI":"10.3390\/diseases10040085"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/blood-2020-137265","article-title":"Duration of response to luspatercept in patients (pts) requiring red blood cell (RBC) transfusions with myelofibrosis (MF)\u2014Updated data from the phase 2 ACE-536-MF-001 study","volume":"136","author":"Gerds","year":"2020","journal-title":"Blood"},{"key":"ref_144","first-page":"805","article-title":"Efficacy and safety of luspatercept versus placebo in patients with myeloproliferative neoplasm-associated myelofibrosis on JAK2 inhibitor therapy and requiring RBC transfusions (INDEPENDENCE trial)","volume":"6","author":"Mesa","year":"2021","journal-title":"HemaSphere"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.2217\/fon-2022-0901","article-title":"BOREAS: A global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed\/refractory myelofibrosis","volume":"18","author":"Verstovsek","year":"2022","journal-title":"Future Oncol."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"abstract S214","DOI":"10.1097\/01.HS9.0000967768.05521.ca","article-title":"Disease modifying activity of navtemadlin (nvtm) correlated with survival outcomes in Janus kinase inhibitor (JAKi) relapsed\/refractory (R\/R) myelofibrosis patients","volume":"7","author":"Vachhani","year":"2023","journal-title":"HemaSphere"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"S362","DOI":"10.1016\/S2152-2650(21)01833-4","article-title":"Clinical benefit of pelabresib (CPI-0610) in combination with ruxolitinib in JAK inhibitor treatment na\u00efve myelofibrosis patients: Interim efficacy subgroup analysis from Arm 3 of the MANIFEST phase 2 study","volume":"21","author":"Gupta","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Mascarenhas, J., Kremyanskaya, M., Patriarca, A., Palandri, F., Devos, T., Passamonti, F., Rampal, R., Mead, A.J., Hobbs, G., and Scandura, J.M. (2023). MANIFEST: Pelabresib in combination with ruxolitinib for Janus kinase inhibitor treatment-na\u00efve myelofibrosis. J. Clin. Oncol., in press.","DOI":"10.1200\/JCO.22.01972"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.2217\/fon-2022-0484","article-title":"Phase, III MANIFEST-2, Pelabresib + ruxolitinib vs. placebo + ruxolitinib in JAK-inhibitor treatment-na\u00efve myelofibrosis","volume":"18","author":"Harrison","year":"2022","journal-title":"Future Oncol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1016\/S2352-3026(22)00116-8","article-title":"Addition of navitoclax to ongoing ruxolitinib treatment in patients with myelofibrosis (REFINE): A post-hoc analysis of molecular markers in a phase 2 study","volume":"9","author":"Pemmaraju","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/01.HS9.0000843680.94912.c5","article-title":"Navitoclax plus ruxolitinib in JAK-inhibitor na\u00efve patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study","volume":"6","author":"Passamonti","year":"2022","journal-title":"HemaSphere"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1182\/blood-2022-157949","article-title":"The combination of navitoclax and ruxolitinib in JAK inhibitor-na\u00efve patients with myelofibrosis mediates responses suggestive of disease modification","volume":"140","author":"Passamonti","year":"2022","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.2217\/fon-2022-0235","article-title":"Imetelstat in intermediate-2 or high-risk myelofibrosis (MF) refractory to Janus kinase inhibitor: IMpactMF phase III study design","volume":"18","author":"Mascarenhas","year":"2022","journal-title":"Future Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1200\/JCO.20.02864","article-title":"Randomized, single-blind, multicenter phase II study of two doses of imetelstat in relapsed or refractory myelofibrosis","volume":"39","author":"Mascarenhas","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1080\/14656566.2023.2203318","article-title":"Cytopenic myelofibrosis: Prevalence, relevance, and treatment","volume":"24","author":"Vachhani","year":"2023","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1182\/hematology.2022000340","article-title":"New approaches to tackle cytopenic myelofibrosis","volume":"2022","author":"Reynolds","year":"2022","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1002\/cncr.34103","article-title":"Improved survival of patients with myelofibrosis in the last decade: Single-center experience","volume":"128","author":"Masarova","year":"2022","journal-title":"Cancer"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00277-021-04682-x","article-title":"Real-world survival of US patients with intermediate- to high-risk myelofibrosis: Impact of ruxolitinib approval","volume":"101","author":"Verstovsek","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1002\/cncr.34707","article-title":"Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies","volume":"129","author":"Verstovsek","year":"2023","journal-title":"Cancer"},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Masarova, L., Bose, P., Pemmaraju, N., Daver, N.G., Sasaki, K., Chifotides, H.T., Zhou, L., Kantarjian, H.M., Estrov, Z., and Verstovsek, S. (2023). The role of therapy in the outcome of patients with myelofibrosis. Cancer, in press.","DOI":"10.1002\/cncr.34851"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1038\/s41375-022-01637-7","article-title":"Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis","volume":"36","author":"Mesa","year":"2022","journal-title":"Leukemia"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/13\/3331\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:59:59Z","timestamp":1760126399000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/13\/3331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,24]]},"references-count":162,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["cancers15133331"],"URL":"https:\/\/doi.org\/10.3390\/cancers15133331","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,24]]}}}